Laura Nisenbaum

Laura Nisenbaum, PhD, is Interim Chief Science Officer at the Alzheimer’s Drug Discovery Foundation (ADDF), where she leads scientific strategy across therapeutics, biomarkers, and prevention. In collaboration with Gates Ventures, she also directs the Diagnostics Accelerator, advancing innovative tools and biomarkers to improve dementia diagnosis and care. Dr. Nisenbaum brings more than 30 years of experience spanning biotechnology, industry, and academia. Before joining ADDF, she served as Senior Director of Aducanumab Biomarkers and Diagnostic Pathways at Biogen and spent 20 years at Eli Lilly in leadership roles across translational medicine, preclinical discovery, and early clinical development. A former Fulbright Scholar, she earned her PhD in neuroscience from the University of Pittsburgh and completed postdoctoral training at the National Institutes of Health and the University of Tennessee. Throughout her career, Dr. Nisenbaum has helped advance more than 15 novel therapeutics